Introduction Multiple antiretroviral agents have demonstrated efficacy for human
immunodeficiency virus (HIV) pre‐exposure prophylaxis (PrEP). As a result, clinical trials of …

Background HIV pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV
acquisition. To enable routine commissioning of PrEP in England, we aimed to establish …

Background HIV pre-exposure prophylaxis (PrEP) data in men who have sex with men
(MSM) in west Africa are essential to guide its large-scale implementation. We assessed the …

Introduction Men who have sex with men (MSM) are disproportionately affected by HIV due
to their increased risk of infection. Oral pre-exposure prophylaxis (PrEP) is a highly effictive …

Background Pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV and has
the potential to significantly impact the HIV epidemic. Given limited resources for HIV …

Introduction: Randomized trials of new agents for HIV pre-exposure prophylaxis (PrEP)
compare against emtricitabine and tenofovir disoproxil fumarate (F/TDF), without a placebo …

Background. A novel translational pharmacology investigation was conducted by combining
an in vitro efficacy target with mucosal tissue pharmacokinetic (PK) data and mathematical …

To date, six clinical trials have explored the efficacy of pre-exposure prophylaxis (PrEP)
against HIV infection using oral tenofovir and/or emtricitabine/tenofovir [1–6]. Efficacy ranged …

Methods: We developed a decision analytic model to evaluate a strategy of daily oral PrEP
during pregnancy and breastfeeding in SSA. We approached the analysis from a health care …

Background Daily pre-exposure prophylaxis (PrEP) is effective in preventing HIV, but few
long-term data are available on effectiveness and adherence in real-world settings. Here …